NO2019038I1 - Risankizumab - Google Patents

Risankizumab

Info

Publication number
NO2019038I1
NO2019038I1 NO2019038C NO2019038C NO2019038I1 NO 2019038 I1 NO2019038 I1 NO 2019038I1 NO 2019038 C NO2019038 C NO 2019038C NO 2019038 C NO2019038 C NO 2019038C NO 2019038 I1 NO2019038 I1 NO 2019038I1
Authority
NO
Norway
Prior art keywords
risankizumab
Prior art date
Application number
NO2019038C
Other languages
English (en)
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US41015810P priority Critical
Priority to US41195310P priority
Priority to US41259410P priority
Priority to US201161448785P priority
Priority to PCT/US2011/058869 priority patent/WO2012061448A1/en
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of NO2019038I1 publication Critical patent/NO2019038I1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or anti-inflammatory agents, e.g antirheumatic agents; Non-steroidal anti-inflammatory drugs (NSAIDs)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance
NO2019038C 2010-11-04 2019-10-17 Risankizumab NO2019038I1 (no)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US41015810P true 2010-11-04 2010-11-04
US41195310P true 2010-11-10 2010-11-10
US41259410P true 2010-11-11 2010-11-11
US201161448785P true 2011-03-03 2011-03-03
PCT/US2011/058869 WO2012061448A1 (en) 2010-11-04 2011-11-02 Anti-il-23 antibodies

Publications (1)

Publication Number Publication Date
NO2019038I1 true NO2019038I1 (no) 2019-10-17

Family

ID=44936573

Family Applications (1)

Application Number Title Priority Date Filing Date
NO2019038C NO2019038I1 (no) 2010-11-04 2019-10-17 Risankizumab

Country Status (39)

Country Link
US (4) US8778346B2 (no)
EP (4) EP2635601B1 (no)
JP (3) JP6126532B2 (no)
KR (2) KR102049223B1 (no)
CN (2) CN103282382B (no)
AP (1) AP3953A (no)
AR (1) AR083747A1 (no)
AU (2) AU2011323426B2 (no)
BR (1) BR112013011065A2 (no)
CA (2) CA2816950C (no)
CO (1) CO6801628A2 (no)
CY (1) CY1118014T1 (no)
DK (1) DK2635601T3 (no)
EA (2) EA030436B1 (no)
EC (1) ECSP13012649A (no)
ES (1) ES2593754T3 (no)
GE (1) GEP201706733B (no)
HK (1) HK1247940A1 (no)
HR (1) HRP20161141T1 (no)
HU (2) HUE030916T2 (no)
IL (2) IL225648A (no)
LT (2) LT2635601T (no)
LU (1) LUC00132I2 (no)
MA (1) MA34641B1 (no)
ME (1) ME02499B (no)
MX (2) MX362039B (no)
MY (1) MY162791A (no)
NL (1) NL301013I2 (no)
NO (1) NO2019038I1 (no)
NZ (1) NZ610592A (no)
PE (1) PE20141162A1 (no)
PL (1) PL2635601T3 (no)
PT (1) PT2635601T (no)
RS (1) RS55161B1 (no)
SG (2) SG10201604605VA (no)
SI (1) SI2635601T1 (no)
TW (2) TWI653242B (no)
UY (1) UY33703A (no)
WO (1) WO2012061448A1 (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
LT2635601T (lt) 2010-11-04 2016-10-10 Boehringer Ingelheim International Gmbh Antikūnai prieš il-23
AU2013256724A1 (en) * 2012-05-03 2014-10-30 Boehringer Ingelheim International Gmbh Anti-IL-23p19 antibodies
TWI636063B (zh) * 2013-03-08 2018-09-21 美國禮來大藥廠 結合il-23之抗體
CN105209064A (zh) 2013-03-15 2015-12-30 美国安进公司 使用抗il-23抗体治疗银屑病的方法
US10507241B2 (en) 2014-07-24 2019-12-17 Boehringer Ingelheim International Gmbh Biomarkers useful in the treatment of IL-23A related diseases
KR20170044751A (ko) 2014-09-03 2017-04-25 베링거잉겔하임인터내쇼날유한회사 Il-23a 및 tnf-알파를 표적으로 하는 화합물 및 이의 용도
US20160222102A1 (en) * 2015-02-04 2016-08-04 Boehringer Ingelheim International Gmbh Methods of treating inflammatory diseases
US20160304602A1 (en) 2015-04-14 2016-10-20 Boehringer Ingelheim International Gmbh Methods of treating diseases
WO2017015433A2 (en) 2015-07-23 2017-01-26 Boehringer Ingelheim International Gmbh Compound targeting il-23a and b-cell activating factor (baff) and uses thereof
WO2017049035A1 (en) * 2015-09-17 2017-03-23 Amgen Inc. Prediction of clinical response to il23-antagonists using il23 pathway biomarkers
TW201722474A (zh) 2015-09-18 2017-07-01 百靈佳殷格翰國際股份有限公司 治療發炎性疾病之方法
EP3370768A4 (en) * 2015-11-03 2019-07-24 Janssen Biotech, Inc. Antibodies specifically binding pd-1 and their uses
EP3443005A1 (en) 2016-04-15 2019-02-20 Boehringer Ingelheim International GmbH Methods of treating inflammatory diseases
US20180105588A1 (en) * 2016-10-14 2018-04-19 Boehringer Ingelheim International Gmbh Methods of treating diseases
TW201946657A (zh) * 2018-03-30 2019-12-16 美商美國禮來大藥廠 治療潰瘍性結腸炎之方法
WO2020012244A2 (en) 2018-07-13 2020-01-16 Allergan Pharmaceuticals International Limited Treating ulcerative colitis with brazikumab
CN109810947A (zh) * 2019-01-18 2019-05-28 北京贝来生物科技有限公司 一种抑制Th17细胞活化的间充质干细胞及其制备方法和应用

Family Cites Families (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
JPS6023084B2 (no) 1979-07-11 1985-06-05 Ajinomoto Kk
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
JP2783294B2 (ja) 1988-09-23 1998-08-06 カイロン コーポレーション 増強された細胞増殖、培養寿命および生産物発現のための細胞培養培地
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
DE69233254T2 (de) 1991-06-14 2004-09-16 Genentech, Inc., South San Francisco Humanisierter Heregulin Antikörper
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
MX9305070A (es) 1992-08-21 1994-04-29 Genentech Inc Compocicion farmaceutica que contiene un antagonista de lfa-1 para el tratamiento de transtornos o desordenes mediados por el lfa-1
DE69329503T2 (de) 1992-11-13 2001-05-03 Idec Pharma Corp Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
ZA9806596B (en) 1997-07-25 1999-02-08 Schering Corp Mammalian cytokine related reagents
US6060284A (en) 1997-07-25 2000-05-09 Schering Corporation DNA encoding interleukin-B30
AU2661199A (en) 1998-02-06 1999-08-23 Schering Corporation Mammalian receptor proteins; related reagents and methods
AT474849T (de) 1998-04-14 2010-08-15 Chugai Pharmaceutical Co Ltd Neues cytokinartiges protein
AT389019T (de) 1999-09-09 2008-03-15 Schering Corp Interleukin-12 p40 und interleukin-b30. kombinationen davon. antikörper. verwendungen in pharmazeutische zusammensetzungen
US7090847B1 (en) 1999-09-09 2006-08-15 Schering Corporation Mammalian cytokines; related reagents and methods
SI1287130T1 (sl) 2000-05-10 2008-08-31 Schering Corp Proteini podenote sesalskega receptorja citokina, s tem povezani reagenti in postopki
US7422743B2 (en) 2000-05-10 2008-09-09 Schering Corporation Mammalian receptor protein DCRS5;methods of treatment
US20050039222A1 (en) 2001-10-24 2005-02-17 Kiyoshi Habu Sgrf gene-modified non-human animals
IL161677D0 (en) 2001-11-08 2004-09-27 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies
JP5477998B2 (ja) 2002-10-30 2014-04-23 ジェネンテック, インコーポレイテッド Il−17産生の阻害
CA2506672C (en) 2002-12-23 2012-04-17 Schering Corporation Il-23 for treating cutaneous wounds
WO2004071517A2 (en) 2003-02-06 2004-08-26 Schering Corporation Uses of il-23 related reagents
US7282204B2 (en) 2003-03-10 2007-10-16 Schering Corporation Uses of IL-23 agonists and antagonists; related reagents
WO2005005612A2 (en) 2003-07-01 2005-01-20 University Of Virginia Patent Foundation Tag-1 and tag-2 proteins and uses thereof
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
WO2005044855A2 (en) 2003-11-04 2005-05-19 Chiron Corporation Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma
PL1682180T3 (pl) 2003-11-04 2010-04-30 Novartis Vaccines And Diagnostics Inc Antagonistyczne przeciwciała monoklonalne anty-CD40 i sposoby ich zastosowania
US20050100965A1 (en) 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
WO2005079837A1 (en) 2004-02-17 2005-09-01 Schering Corporation Methods of modulating il-23 activity; related reagents
US20050287593A1 (en) 2004-05-03 2005-12-29 Schering Corporation Use of cytokine expression to predict skin inflammation; methods of treatment
CN1993480A (zh) 2004-05-03 2007-07-04 先灵公司 Il-17表达预测皮肤炎症的用途;治疗方法
AU2005289594B2 (en) * 2004-09-27 2012-02-02 Centocor, Inc. Srage mimetibody, compositions, methods and uses
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
TWI363091B (en) 2004-12-20 2012-05-01 Schering Corp Uses of mammalian cytokine; related reagents
US20090142855A1 (en) 2005-06-30 2009-06-04 Wei Tang Polynucleotides and Polypeptides of the IL-12 Family of Cytokines
HUE042561T2 (hu) 2005-06-30 2019-07-29 Janssen Biotech Inc Anti-IL-23-ellenanyagok, készítmények, eljárások és alkalmazások
CN101248088A (zh) * 2005-08-25 2008-08-20 伊莱利利公司 抗il-23抗体
ES2347690T3 (es) * 2005-08-25 2010-11-03 Eli Lilly And Company Anticuerpos anti-il-23.
PT1931710T (pt) * 2005-08-31 2017-03-28 Merck Sharp & Dohme Anticorpos anti-il-23 manipulados
PT1933869E (pt) 2005-09-01 2009-12-24 Schering Corp Utilização de antagonistas de il-23 e il-para tratar a doença inflamatória ocular auto-imune
BRPI0620914A2 (pt) 2005-12-28 2011-11-29 Centocor Inc marcadores e métodos para avaliar e tratar psorìase e distúrbios relacionados
EA201301072A1 (ru) 2005-12-29 2014-06-30 Сентокор, Инк. Антитела против il-23p19 и их применение
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
US20080311043A1 (en) 2006-06-08 2008-12-18 Hoffman Rebecca S Uses and compositions for treatment of psoriatic arthritis
AU2007260787A1 (en) 2006-06-13 2007-12-21 Zymogenetics, Inc IL-17 and IL-23 antagonists and methods of using the same
MX2008015446A (es) 2006-06-19 2008-12-12 Wyeth Corp Metodos de modulacion il-22 e il-17.
TW200837080A (en) 2007-01-09 2008-09-16 Wyeth Corp Anti-IL-13 antibody formulations and uses thereof
TWI426918B (zh) 2007-02-12 2014-02-21 Merck Sharp & Dohme Il-23拮抗劑於治療感染之用途
CA2675602A1 (en) 2007-02-16 2008-08-21 Wyeth Protein formulations containing sorbitol
MX2009009080A (es) 2007-02-23 2009-11-02 Schering Corp Anticuerpos anti-interleucina-23p19 manipulados por ingenieria genetica.
HUE042172T2 (hu) 2007-02-23 2019-06-28 Merck Sharp & Dohme Genetikailag elõállított anti-il-23P19 antitestek
CA2679400A1 (en) 2007-02-28 2008-09-04 Schering Corporation Combination therapy for treatment of immune disorders
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
WO2009032954A1 (en) 2007-09-04 2009-03-12 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Deletions in domain ii of pseudomonas exotoxin a that reduce non-specific toxicity
AR068723A1 (es) 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
EP2212442A1 (en) 2007-10-26 2010-08-04 Galderma Research & Development Non-invasive method to perform skin inflammatory disease pharmaco-genomic studies and diagnosis method thereof
CA2607771A1 (en) 2007-11-01 2009-05-01 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of National Defence Humanized anti-venezuelan equine encephalitis virus recombinant antibody
WO2009073569A2 (en) 2007-11-30 2009-06-11 Abbott Laboratories Protein formulations and methods of making same
WO2009082624A2 (en) 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
WO2011066371A2 (en) 2009-11-24 2011-06-03 Alder Biopharmaceuticals, Inc. Antibodies to il-6 and use thereof
US8563697B2 (en) 2008-08-14 2013-10-22 Cephalon Australia Pty. Ltd. Anti-IL-12/IL-23 antibodies
AU2009288419B2 (en) 2008-08-27 2015-08-06 Merck Sharp & Dohme Corp. Lyophilized formulatons of engineered anti-IL-23p19 antibodies
US8257397B2 (en) 2009-12-02 2012-09-04 Spartek Medical, Inc. Low profile spinal prosthesis incorporating a bone anchor having a deflectable post and a compound spinal rod
US20120128689A1 (en) 2009-04-01 2012-05-24 Glaxo Group Limited Anti-il-23 immunoglobulins
EP2414546A4 (en) 2009-04-02 2013-03-13 Univ Johns Hopkins Compositions and methods for treating or preventing inflammatory bowel disease and colon cancer
EP2456787A4 (en) 2009-07-24 2013-01-30 Univ Leland Stanford Junior Cytokine compositions and methods of use thereof
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
BR112012019881A2 (pt) 2010-02-18 2017-06-27 Squibb Bristol Myers Co proteínas de domínio estrutural baseadas na fibronectina que ligam-se à il-23
MX2012009755A (es) 2010-02-26 2012-09-12 Novo Nordisk As Composiciones que contienen anticuerpo estable.
EP2542221A4 (en) 2010-03-01 2013-10-23 Cytodyn Inc Concentrated protein formulations and uses thereof
AU2011268450B2 (en) 2010-06-15 2015-07-16 Amgen (Europe) GmbH Biomarkers for the treatment of psoriasis
US20110311527A1 (en) 2010-06-16 2011-12-22 Allergan, Inc. IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS
EP2596022A4 (en) 2010-07-20 2014-11-05 Cephalon Australia Pty Ltd Anti-il-23 heterodimer specific antibodies
GB201013975D0 (en) 2010-08-20 2010-10-06 Imp Innovations Ltd Method of treating desease
CN103261222B (zh) 2010-09-10 2017-07-28 医疗免疫有限公司 抗体衍生物
LT2635601T (lt) 2010-11-04 2016-10-10 Boehringer Ingelheim International Gmbh Antikūnai prieš il-23
GB201100282D0 (en) 2011-01-07 2011-02-23 Ucb Pharma Sa Biological methods
TW201309330A (zh) 2011-01-28 2013-03-01 Abbott Lab 包含糖基化抗體之組合物及其用途
WO2012104402A1 (en) 2011-02-04 2012-08-09 Ab Science Treatment of severe persitent asthma with masitinib
AU2013256724A1 (en) 2012-05-03 2014-10-30 Boehringer Ingelheim International Gmbh Anti-IL-23p19 antibodies
WO2014004436A2 (en) 2012-06-27 2014-01-03 Merck Sharp & Dohme Corp. Crystalline anti-human il-23 antibodies
AU2014228553B2 (en) 2013-03-15 2019-01-24 Amgen Inc. Methods for treating Crohn's disease using an anti-IL23 antibody
CN105209064A (zh) 2013-03-15 2015-12-30 美国安进公司 使用抗il-23抗体治疗银屑病的方法
KR20140119396A (ko) 2013-03-29 2014-10-10 삼성전자주식회사 단백질 약물의 액상 제형
KR20170044751A (ko) 2014-09-03 2017-04-25 베링거잉겔하임인터내쇼날유한회사 Il-23a 및 tnf-알파를 표적으로 하는 화합물 및 이의 용도
US20160222102A1 (en) 2015-02-04 2016-08-04 Boehringer Ingelheim International Gmbh Methods of treating inflammatory diseases
WO2017015433A2 (en) 2015-07-23 2017-01-26 Boehringer Ingelheim International Gmbh Compound targeting il-23a and b-cell activating factor (baff) and uses thereof
TW201722474A (zh) 2015-09-18 2017-07-01 百靈佳殷格翰國際股份有限公司 治療發炎性疾病之方法

Also Published As

Publication number Publication date
AU2011323426A1 (en) 2013-06-06
RS55161B1 (sr) 2017-01-31
MX343858B (es) 2016-11-25
NZ610592A (en) 2015-03-27
MX2013005015A (es) 2013-08-08
LT2635601T (lt) 2016-10-10
EP3281954A1 (en) 2018-02-14
TWI545133B (zh) 2016-08-11
SI2635601T1 (sl) 2017-01-31
CA2816950C (en) 2018-11-27
JP6126532B2 (ja) 2017-05-10
CA3017116A1 (en) 2012-05-10
EP3115375A1 (en) 2017-01-11
ES2593754T3 (es) 2016-12-13
AU2011323426B2 (en) 2016-09-29
US20190144534A1 (en) 2019-05-16
LUC00132I1 (no) 2019-10-16
AP201306820A0 (en) 2013-04-30
US20140363444A1 (en) 2014-12-11
TW201307386A (zh) 2013-02-16
EP3456740A1 (en) 2019-03-20
EA030436B1 (ru) 2018-08-31
AR083747A1 (es) 2013-03-20
LUC00132I2 (no) 2020-07-16
TWI653242B (zh) 2019-03-11
DK2635601T3 (en) 2016-09-19
EA201300530A1 (ru) 2013-12-30
HUS1900048I1 (hu) 2019-11-28
PE20141162A1 (es) 2014-09-18
PT2635601T (pt) 2016-09-27
IL225648D0 (en) 2013-06-27
LTPA2019518I1 (lt) 2019-11-11
UY33703A (es) 2012-06-29
KR102049223B1 (ko) 2019-11-28
BR112013011065A2 (pt) 2018-09-25
WO2012061448A1 (en) 2012-05-10
CY1118014T1 (el) 2017-05-17
US9441036B2 (en) 2016-09-13
SG190006A1 (en) 2013-06-28
PL2635601T3 (pl) 2017-02-28
ME02499B (me) 2017-02-20
ECSP13012649A (es) 2013-07-31
TW201641516A (zh) 2016-12-01
IL225648A (en) 2016-04-21
HUE030916T2 (en) 2017-06-28
IL244335A (en) 2017-11-30
SG10201604605VA (en) 2016-07-28
US10202448B2 (en) 2019-02-12
US8778346B2 (en) 2014-07-15
CN103282382A (zh) 2013-09-04
HRP20161141T1 (hr) 2016-12-02
NL301013I1 (no) 2019-10-22
EP2635601A1 (en) 2013-09-11
AU2016273970A1 (en) 2017-01-12
MA34641B1 (fr) 2013-11-02
JP6445596B2 (ja) 2018-12-26
GEP201706733B (en) 2017-09-25
EP2635601B1 (en) 2016-07-20
KR101931591B1 (ko) 2018-12-24
CN103282382B (zh) 2017-11-03
AP3953A (en) 2016-12-22
JP2019054809A (ja) 2019-04-11
KR20130139975A (ko) 2013-12-23
MY162791A (en) 2017-07-14
NL301013I2 (nl) 2020-01-09
HK1247940A1 (zh) 2018-10-05
MX362039B (es) 2019-01-07
EA201890548A1 (ru) 2018-07-31
JP2014500009A (ja) 2014-01-09
CN107522784A (zh) 2017-12-29
JP2017079785A (ja) 2017-05-18
US20120282269A1 (en) 2012-11-08
KR20180137588A (ko) 2018-12-27
US20160333091A1 (en) 2016-11-17
IL244335D0 (en) 2016-04-21
AU2018236692A1 (en) 2018-10-11
AU2016273970B2 (en) 2018-06-28
CA2816950A1 (en) 2012-05-10
CO6801628A2 (es) 2013-11-29

Similar Documents

Publication Publication Date Title
NO2019034I1 (no) lorlatinib
NO2017023I2 (no) Venetoklaks
NO2016004I2 (no) Ledipasvir
NO2019006I1 (no) Tisagenlekleucel
NO2019020I1 (no) lanadelumab
NO2020017I1 (no) Siponimod
SMT201600400B (it) Inalatore
NO2019022I1 (no) Natriumzirkoniumsyklosilikat
CO6811812A2 (es) Anticuerpo anti-b7-h3
CO6801628A2 (es) Anticuerpos anti-il-23
NO2018039I1 (no) Rukaparibkamsylat
NO20140526A1 (no) Svanehals-ledningssystem
ITVI20100321A1 (it) Bottiglia
NO20131470A1 (no) Bropluggverktøy
NO20120395A1 (no) Stromningsstyringssystem
NO2010019I2 (no) 6-per-deoksy-6-per-(2-karboksetyl)tio-y-cyklodextrin
CR20130111A (es) Triazina-oxidiazoles
CO6801726A2 (es) Compuestos
CO6960543A2 (es) 2-tiopirimidinonas
NO2017034I1 (no) Idarucizumab
SMT201500078B (it) Fellosilicato modificato
NO340857B1 (no) Tykkvegget komposittrør
NO20100814A1 (no) Tynnkompositter
NO20110970A1 (no) Oppbygget flenslasedeksel
NO20111616A1 (no) Trykkskjot